Symbols / ATAI $4.71 -3.29% AtaiBeckley Inc.

Healthcare • Biotechnology • United States • NGM
ATAI Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Fundamentals
Scroll to Statements
Market Cap 1.72B Enterprise Value 1.52B Income -660.05M Sales 4.09M Book/sh 0.61 Cash/sh 0.70
Dividend Yield — Payout 0.00% Employees 99 IPO — P/E — Forward P/E -9.53
PEG — P/S 420.14 P/B 7.71 P/C — EV/EBITDA -13.84 EV/Sales 372.94
Quick Ratio 11.49 Current Ratio 11.74 Debt/Eq 2.06 LT Debt/Eq — EPS (ttm) -2.91 EPS next Y -0.49
EPS Growth — Revenue Growth — Earnings 2026-05-13 ROA -30.75% ROE -3.90% ROIC —
Gross Margin 0.00% Oper. Margin -35.88% Profit Margin 0.00% Shs Outstand 364.75M Shs Float 302.85M Short Float 7.97%
Short Ratio 4.59 Short Interest — 52W High 6.75 52W Low 1.29 Beta 1.57 Avg Volume 5.54M
Volume 6.58M Target Price $13.92 Recom Strong_buy Prev Close $4.87 Price $4.71 Change -3.29%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$13.92
Mean price target
2. Current target
$4.71
Latest analyst target
3. DCF / Fair value
$-2.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.71
Low
$7.00
High
$25.00
Mean
$13.92

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 main Canaccord Genuity Buy → Buy $15
2026-04-17 main Guggenheim Buy → Buy $16
2026-03-27 init Deutsche Bank — → Buy $12
2026-03-17 reit HC Wainwright & Co. Buy → Buy $25
2026-03-09 reit Needham Buy → Buy $14
2026-03-02 main HC Wainwright & Co. Buy → Buy $25
2026-01-20 init Guggenheim — → Buy $11
2025-12-23 init Jones Trading — → Buy $16
2025-10-22 main Canaccord Genuity Buy → Buy $14
2025-10-13 init Needham — → Buy $12
2025-09-23 reit HC Wainwright & Co. Buy → Buy $15
2025-07-30 main HC Wainwright & Co. Buy → Buy $15
2025-07-29 init Oppenheimer — → Outperform $14
2025-07-28 main Canaccord Genuity Buy → Buy $11
2025-07-02 main Canaccord Genuity Buy → Buy $12
2025-05-20 reit HC Wainwright & Co. Buy → Buy $10
2025-03-19 reit HC Wainwright & Co. Buy → Buy $10
2025-02-13 reit HC Wainwright & Co. Buy → Buy $10
2024-11-18 main HC Wainwright & Co. Buy → Buy $10
2024-11-18 main Canaccord Genuity Buy → Buy $11
News
RSS: Latest ATAI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-08 ANGERMAYER CHRISTIAN Director and Beneficial Owner of more than 10% of a Class of Security — 559,232 $1.34 $897,297
2026-03-20 CRAIG KEVIN JAMES M.D. Officer — 100,000 $3.55 $355,000
2026-03-20 CRAIG KEVIN JAMES M.D. Officer — 100,000 $1.18 $125,608
2026-01-02 FEILDING-MELLEN COSMO Director — 39,594 $3.90 $154,377
2025-11-05 FEILDING-MELLEN COSMO Director — 7,702,990 — —
2025-09-30 APEIRON INVESTMENT GROUP LTD. Beneficial Owner of more than 10% of a Class of Security — 2,367,200 — —
2025-08-14 APEIRON INVESTMENT GROUP LTD. Beneficial Owner of more than 10% of a Class of Security — 8,675,799 $2.19 $19,000,000
2025-03-24 APEIRON INVESTMENT GROUP LTD. Beneficial Owner of more than 10% of a Class of Security — 1,800,000 $1.40 $2,520,000
2025-03-21 RAO SRINIVAS Chief Executive Officer — 75,418 $1.35 $101,814
2025-03-21 KIRPEKAR SAHIL Officer — 48,563 $1.35 $65,560
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4.09
+1227.60%
0.31
-1.91%
0.31
+34.76%
0.23
Operating Revenue
4.09
+1227.60%
0.31
-1.91%
0.31
+34.76%
0.23
Operating Expense
117.44
+14.60%
102.47
-16.92%
123.34
-14.74%
144.66
Research And Development
53.06
-4.32%
55.45
-10.85%
62.20
-16.30%
74.31
Selling General And Administration
65.09
+36.90%
47.54
-25.22%
63.58
-9.62%
70.35
General And Administrative Expense
65.09
+36.90%
47.54
-25.22%
63.58
-9.62%
70.35
Other Gand A
65.09
+36.90%
47.54
-25.22%
63.58
-9.62%
70.35
Other Operating Expenses
—
-0.53
+78.53%
-2.44
—
Total Expenses
117.44
+14.60%
102.47
-16.92%
123.34
-14.74%
144.66
Operating Income
-113.35
-10.94%
-102.17
+16.96%
-123.03
+14.82%
-144.43
Total Operating Income As Reported
-644.06
-527.18%
-102.69
+18.16%
-125.47
+13.34%
-144.79
EBITDA
-657.67
-354.17%
-144.81
-298.80%
-36.31
+72.92%
-134.09
Normalized EBITDA
-113.45
-19.40%
-95.02
+21.51%
-121.05
+16.06%
-144.20
Reconciled Depreciation
1.01
+113.95%
0.47
+48.28%
0.32
+89.88%
0.17
EBIT
-658.69
-353.39%
-145.28
-296.62%
-36.63
+72.72%
-134.26
Total Unusual Items
-544.23
-993.03%
-49.79
-158.76%
84.74
+737.99%
10.11
Total Unusual Items Excluding Goodwill
-544.23
-993.03%
-49.79
-158.76%
84.74
+737.99%
10.11
Special Income Charges
-525.51
-45169.90%
1.17
+222.61%
-0.95
-184.38%
1.13
Other Special Charges
524.82
—
—
0.36
Restructuring And Mergern Acquisition
—
-5.57
0.00
+100.00%
-2.96
Write Off
—
0.00
-100.00%
1.01
0.00
Net Income
-660.05
-342.19%
-149.27
-271.09%
-40.22
+73.60%
-152.38
Pretax Income
-659.85
-344.63%
-148.41
-277.76%
-39.29
+70.94%
-135.18
Net Non Operating Interest Income Expense
0.32
+113.47%
-2.35
-189.99%
-0.81
-115.73%
-0.38
Interest Expense Non Operating
1.16
-62.80%
3.12
+17.62%
2.66
+187.76%
0.92
Net Interest Income
0.32
+113.47%
-2.35
-189.99%
-0.81
-115.73%
-0.38
Interest Expense
1.16
-62.80%
3.12
+17.62%
2.66
+187.76%
0.92
Interest Income Non Operating
1.48
+89.97%
0.78
-57.88%
1.85
+237.04%
0.55
Interest Income
1.48
+89.97%
0.78
-57.88%
1.85
+237.04%
0.55
Other Income Expense
-546.82
-1145.80%
-43.89
-151.91%
84.55
+778.61%
9.62
Other Non Operating Income Expenses
-2.59
-143.90%
5.90
+3220.63%
-0.19
+61.35%
-0.49
Gain On Sale Of Security
-18.71
+63.27%
-50.96
-159.47%
85.69
+853.69%
8.98
Gain On Sale Of Business
0.00
-100.00%
1.17
+1843.33%
0.06
-95.96%
1.48
Tax Provision
0.30
+183.71%
-0.36
-135.04%
1.02
-83.69%
6.23
Tax Rate For Calcs
0.00
+8653.65%
0.00
-98.86%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-114.29
-95586.06%
-0.12
-100.67%
17.79
+737.99%
2.12
Net Income Including Noncontrolling Interests
-660.15
-339.95%
-150.05
-241.84%
-43.90
+72.12%
-157.42
Net Income From Continuing Operation Net Minority Interest
-660.05
-342.19%
-149.27
-271.09%
-40.22
+73.60%
-152.38
Net Income From Continuing And Discontinued Operation
-660.05
-342.19%
-149.27
-271.09%
-40.22
+73.60%
-152.38
Net Income Continuous Operations
-660.15
-339.95%
-150.05
-241.84%
-43.90
+72.12%
-157.42
Minority Interests
0.10
-87.18%
0.78
-78.75%
3.67
-27.05%
5.03
Normalized Income
-230.11
-131.04%
-99.60
+7.06%
-107.17
+33.18%
-160.37
Net Income Common Stockholders
-660.05
-342.19%
-149.27
-271.09%
-40.22
+73.60%
-152.38
Diluted EPS
-2.91
-212.90%
-0.93
-272.00%
-0.25
+74.49%
-0.98
Basic EPS
-2.91
-212.90%
-0.93
-272.00%
-0.25
+74.49%
-0.98
Basic Average Shares
226.53
+41.44%
160.16
+0.83%
158.83
+2.00%
155.72
Diluted Average Shares
226.53
+41.44%
160.16
+0.83%
158.83
+2.00%
155.72
Diluted NI Availto Com Stockholders
-660.05
-342.19%
-149.27
-271.09%
-40.22
+73.60%
-152.38
Earnings From Equity Interest
—
—
—
—
Earnings From Equity Interest Net Of Tax
0.00
+100.00%
-2.00
+44.34%
-3.59
+77.55%
-16.01
Gain On Sale Of PPE
-0.69
0.00
—
—
Other Taxes
-0.71
-36.00%
-0.53
—
—
Line Item Trend 2023-12-31
Total Assets
293.48
Current Assets
185.59
Cash Cash Equivalents And Short Term Investments
179.26
Cash And Cash Equivalents
45.03
Other Short Term Investments
134.22
Receivables
2.26
Accounts Receivable
—
Taxes Receivable
1.75
Prepaid Assets
3.23
Restricted Cash
0.00
Other Current Assets
0.85
Total Non Current Assets
107.89
Net PPE
2.20
Gross PPE
2.36
Accumulated Depreciation
-0.15
Properties
—
Machinery Furniture Equipment
1.13
Other Properties
1.22
Leases
—
Goodwill And Other Intangible Assets
1.77
Goodwill
0.00
Other Intangible Assets
1.77
Investments And Advances
91.66
Long Term Equity Investment
—
Other Investments
89.83
Non Current Deferred Assets
—
Other Non Current Assets
0.95
Total Liabilities Net Minority Interest
49.16
Current Liabilities
20.12
Payables And Accrued Expenses
18.74
Payables
5.30
Accounts Payable
4.59
Current Accrued Expenses
13.44
Total Tax Payable
0.71
Current Debt And Capital Lease Obligation
0.28
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
0.28
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
1.10
Total Non Current Liabilities Net Minority Interest
29.04
Long Term Debt And Capital Lease Obligation
18.87
Long Term Debt
17.88
Long Term Capital Lease Obligation
0.99
Other Non Current Liabilities
10.18
Stockholders Equity
242.96
Common Stock Equity
242.96
Capital Stock
18.57
Common Stock
18.57
Preferred Stock
—
Share Issued
166.03
Ordinary Shares Number
166.03
Treasury Shares Number
0.00
Additional Paid In Capital
794.79
Retained Earnings
-550.94
Gains Losses Not Affecting Retained Earnings
-19.46
Minority Interest
1.35
Other Equity Adjustments
-19.46
Total Equity Gross Minority Interest
244.32
Total Capitalization
260.84
Working Capital
165.47
Invested Capital
260.84
Total Debt
19.14
Net Debt
—
Capital Lease Obligations
1.26
Net Tangible Assets
241.19
Tangible Book Value
241.19
Available For Sale Securities
1.84
Derivative Product Liabilities
—
Investmentin Financial Assets
1.84
Investments In Other Ventures Under Equity Method
—
Non Current Note Receivables
11.30
Notes Receivable
0.51
Other Equity Interest
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-102.67
-24.55%
-82.44
+2.00%
-84.12
+19.48%
-104.47
Cash Flow From Continuing Operating Activities
-102.67
-24.55%
-82.44
+2.00%
-84.12
+19.48%
-104.47
Net Income From Continuing Operations
-660.15
-339.95%
-150.05
-241.84%
-43.90
+72.12%
-157.42
Depreciation Amortization Depletion
1.01
+113.95%
0.47
+48.28%
0.32
+89.88%
0.17
Depreciation And Amortization
1.01
+113.95%
0.47
+48.28%
0.32
+89.88%
0.17
Other Non Cash Items
26.81
-39.81%
44.54
+151.59%
-86.34
-4816.63%
-1.76
Stock Based Compensation
14.21
-44.24%
25.49
-22.72%
32.98
-22.17%
42.38
Asset Impairment Charge
0.03
-99.08%
3.58
+254.01%
1.01
+18.66%
0.85
Deferred Tax
—
—
0.00
-100.00%
5.07
Deferred Income Tax
—
—
0.00
-100.00%
5.07
Operating Gains Losses
521.88
+79942.79%
0.65
-84.95%
4.33
-54.74%
9.57
Gain Loss On Investment Securities
527.56
+41970.08%
-1.26
—
-0.34
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
2.08
0.00
+100.00%
-0.27
Net Foreign Currency Exchange Gain Loss
-2.02
-287.76%
1.08
+34.92%
0.80
+116.14%
-4.95
Gain Loss On Sale Of PPE
0.69
0.00
—
—
Change In Working Capital
-6.47
+29.62%
-9.20
-223.18%
7.47
+323.96%
-3.33
Change In Prepaid Assets
0.69
+163.34%
-1.09
-112.59%
8.66
+669.19%
-1.52
Change In Payables And Accrued Expense
-7.93
+10.17%
-8.83
-639.53%
-1.19
+34.14%
-1.81
Change In Accrued Expense
-6.24
+10.36%
-6.96
-108.82%
-3.33
-372.89%
1.22
Change In Payable
-1.70
+9.46%
-1.87
-187.56%
2.14
+170.47%
-3.03
Change In Account Payable
-1.70
+9.46%
-1.87
-187.56%
2.14
+170.47%
-3.03
Change In Other Working Capital
0.77
+6.24%
0.72
—
—
Investing Cash Flow
-109.13
-284.42%
59.17
+211.03%
-53.30
+38.63%
-86.85
Cash Flow From Continuing Investing Activities
-109.13
-284.42%
59.17
+211.03%
-53.30
+38.63%
-86.85
Net PPE Purchase And Sale
-0.90
-14916.67%
-0.01
+97.68%
-0.26
+66.49%
-0.77
Purchase Of PPE
-0.90
-14916.67%
-0.01
+97.68%
-0.26
+66.49%
-0.77
Capital Expenditure
-10.87
-11340.00%
-0.10
+83.90%
-0.59
+42.38%
-1.02
Capital Expenditure Reported
0.00
+100.00%
-0.09
+73.11%
-0.33
-31.87%
-0.25
Net Investment Purchase And Sale
-92.89
-239.37%
66.65
+242.58%
-46.75
+43.56%
-82.82
Purchase Of Investment
-101.94
-579.63%
-15.00
+91.94%
-186.22
+39.86%
-309.66
Sale Of Investment
9.05
-88.92%
81.65
-41.45%
139.47
-38.51%
226.83
Net Business Purchase And Sale
4.64
+1191.36%
0.36
+181.04%
-0.44
0.00
Purchase Of Business
—
0.00
+100.00%
-0.44
0.00
Gain Loss On Sale Of Business
-6.90
-491.94%
-1.17
-1843.33%
-0.06
+95.96%
-1.48
Net Intangibles Purchase And Sale
-9.97
0.00
0.00
—
Purchase Of Intangibles
-9.97
0.00
0.00
—
Net Other Investing Changes
-10.00
-29.12%
-7.75
-40.49%
-5.51
-83.77%
-3.00
Financing Cash Flow
269.48
+4914.53%
5.37
+164.32%
-8.36
-140.20%
20.79
Cash Flow From Continuing Financing Activities
269.48
+4914.53%
5.37
+164.32%
-8.36
-140.20%
20.79
Net Issuance Payments Of Debt
0.00
-100.00%
5.00
0.00
-100.00%
15.00
Issuance Of Debt
0.00
-100.00%
5.00
0.00
-100.00%
15.00
Long Term Debt Issuance
0.00
-100.00%
5.00
0.00
-100.00%
15.00
Net Long Term Debt Issuance
0.00
-100.00%
5.00
0.00
-100.00%
15.00
Net Common Stock Issuance
251.49
0.00
—
0.00
Common Stock Payments
-6.63
0.00
—
—
Repurchase Of Capital Stock
-6.63
0.00
—
—
Proceeds From Stock Option Exercised
31.94
+5870.09%
0.54
+160.98%
0.20
-91.06%
2.29
Net Other Financing Charges
-13.95
-8565.84%
-0.16
+98.12%
-8.56
-396.09%
2.89
Changes In Cash
57.68
+422.39%
-17.89
+87.73%
-145.77
+14.52%
-170.53
Effect Of Exchange Rate Changes
0.12
-67.96%
0.36
+91.53%
0.19
+116.83%
-1.12
Beginning Cash Position
27.50
-38.92%
45.03
-76.37%
190.61
-47.38%
362.27
End Cash Position
85.30
+210.13%
27.50
-38.92%
45.03
-76.37%
190.61
Free Cash Flow
-113.54
-37.57%
-82.53
+2.57%
-84.71
+19.70%
-105.49
Interest Paid Supplemental Data
0.79
-63.27%
2.16
+12.27%
1.92
—
Income Tax Paid Supplemental Data
0.59
+43.31%
0.41
-72.14%
1.48
—
Common Stock Issuance
258.13
0.00
—
0.00
Earnings Losses From Equity Investments
0.00
-100.00%
2.00
-44.34%
3.59
-77.55%
16.01
Issuance Of Capital Stock
258.13
0.00
0.00
-100.00%
0.60
Net Preferred Stock Issuance
—
—
0.00
-100.00%
0.60
Preferred Stock Issuance
—
—
0.00
-100.00%
0.60
Sale Of Business
4.64
+1191.36%
0.36
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category